Recent advances in the management of pulmonary sarcomatoid carcinoma

References

• Travis WDBE, Burke AP, Marx A, et al. World Health Organization classification of tumours of the lung, pleura, thymus and heart. 4th ed. Lyon: WHO Press; 2015.
   Google Scholar
• Yendamuri S, Caty L, Pine M, et al. Outcomes of sarcomatoid carcinoma of the lung: a Surveillance, Epidemiology, and End Results Database analysis. Surgery. 2012;152:397–402.
   PubMed Web of Science ®Google Scholar
• Mochizuki T, Ishii G, Nagai K, et al. Pleomorphic carcinoma of the lung: clinicopathologic characteristics of 70 cases. Am J Surg Pathol. 2008;32:1727–1735.
   PubMed Web of Science ®Google Scholar
• Pelosi G, Fraggetta F, Nappi O, et al. Pleomorphic carcinomas of the lung show a selective distribution of gene products involved in cell differentiation, cell cycle control, tumor growth, and tumor cell motility: a clinicopathologic and immunohistochemical study of 31 cases. Am J Surg Pathol. 2003;27:1203–1215.
   PubMed Web of Science ®Google Scholar
• Rossi G, Cavazza A, Sturm N, et al. Pulmonary carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements: a clinicopathologic and immunohistochemical study of 75 cases. Am J Surg Pathol. 2003;27:311–324.
   PubMed Web of Science ®Google Scholar
• Yuki T, Sakuma T, Ohbayashi C, et al. Pleomorphic carcinoma of the lung: a surgical outcome. J Thorac Cardiovasc Surg. 2007;134:399–404.
   PubMed Web of Science ®Google Scholar
• Blaukovitsch M, Halbwedl I, Kothmaier H, et al. Sarcomatoid carcinomas of the lung–are these histogenetically heterogeneous tumors? Virchows Arch. 2006;449:455–461.
   PubMed Web of Science ®Google Scholar
• Litzky LA. Pulmonary sarcomatous tumors. Arch Pathol Lab Med. 2008;132:1104–1117.
   PubMed Web of Science ®Google Scholar
• Pelosi G, Sonzogni A, De Pas T, et al. Review article: pulmonary sarcomatoid carcinomas: a practical overview. Int J Surg Pathol. 2010;18:103–120.
   PubMed Web of Science ®Google Scholar
• Fishback NF, Travis WD, Moran CA, et al. Pleomorphic (spindle/giant cell) carcinoma of the lung. A clinicopathologic correlation of 78 cases. Cancer. 1994;73:2936–2945.
   PubMed Web of Science ®Google Scholar
• Koss MN, Hochholzer L, Frommelt RA. Carcinosarcomas of the lung: a clinicopathologic study of 66 patients. Am J Surg Pathol. 1999;23:1514–1526.
   PubMed Web of Science ®Google Scholar
• Nappi O, Glasner SD, Swanson PE, et al. Biphasic and monophasic sarcomatoid carcinomas of the lung. A reappraisal of ‘carcinosarcomas’ and ‘spindle-cell carcinomas’. Am J Clin Pathol. 1994;102:331–340.
   PubMed Web of Science ®Google Scholar
• Travis WD. Sarcomatoid neoplasms of the lung and pleura. Arch Pathol Lab Med. 2010;134:1645–1658.
   PubMed Web of Science ®Google Scholar
• Francis D, Jacobsen M. Pulmonary blastoma. Curr Top Pathol. 1983;73:265–294.
   PubMedGoogle Scholar
• Franks TJ, Galvin JR. Sarcomatoid carcinoma of the lung: histologic criteria and common lesions in the differential diagnosis. Arch Pathol Lab Med. 2010;134:49–54.
   PubMed Web of Science ®Google Scholar
• Davis MP, Eagan RT, Weiland LH, et al. Carcinosarcoma of the lung: Mayo Clinic experience and response to chemotherapy. Mayo Clin Proc. 1984;59:598–603.
   PubMed Web of Science ®Google Scholar
• Koss MN, Hochholzer L, O’Leary T. Pulmonary blastomas. Cancer. 1991;67:2368–2381.
   PubMed Web of Science ®Google Scholar
• Shin MS, Jackson LK, Shelton RW Jr, et al. Giant cell carcinoma of the lung. Clinical and roentgenographic manifestations. Chest. 1986;89:366–369.
   PubMed Web of Science ®Google Scholar
• Nakajima M, Kasai T, Hashimoto H, et al. Sarcomatoid carcinoma of the lung: a clinicopathologic study of 37 cases. Cancer. 1999;86:608–616.
   PubMed Web of Science ®Google Scholar
• Attanoos RL, Papagiannis A, Suttinont P, et al. Pulmonary giant cell carcinoma: pathological entity or morphological phenotype? Histopathology. 1998;32:225–231.
   PubMed Web of Science ®Google Scholar
• Ginsberg SS, Buzaid AC, Stern H, et al. Giant cell carcinoma of the lung. Cancer. 1992;70:606–610.
   PubMed Web of Science ®Google Scholar
• Robert J, Pache J-C, Seium Y, et al. Pulmonary blastoma: report of five cases and identification of clinical features suggestive of the disease. Eur J Cardiothorac Surg. 2002;22:708–711.
   PubMedGoogle Scholar
• Chaft JE, Sima CS, Ginsberg MS, et al. Clinical outcomes with perioperative chemotherapy in sarcomatoid carcinomas of the lung. J Thorac Oncol. 2012;7:1400–1405.
   PubMed Web of Science ®Google Scholar
• Ito K, Oizumi S, Fukumoto S, et al. Clinical characteristics of pleomorphic carcinoma of the lung. Lung Cancer. 2010;68:204–210.
   PubMed Web of Science ®Google Scholar
• Martin LW, Correa AM, Ordonez NG, et al. Sarcomatoid carcinoma of the lung: a predictor of poor prognosis. Ann Thorac Surg. 2007;84:973–980.
   PubMed Web of Science ®Google Scholar
• Park JS, Lee Y, Han J, et al. Clinicopathologic outcomes of curative resection for sarcomatoid carcinoma of the lung. Oncology. 2011;81:206–213.
   PubMed Web of Science ®Google Scholar
• Raveglia F, Mezzetti M, Panigalli T, et al. Personal experience in surgical management of pulmonary pleomorphic carcinoma. Ann Thorac Surg. 2004;78:1742–1747.
   PubMed Web of Science ®Google Scholar
• Sökücü SN, Kocatürk C, Ürer N, et al. Evaluation of six patients with pulmonary carcinosarcoma with a literature review. ScientificWorldJournal. 2012;2012:1–5.
   Web of Science ®Google Scholar
• Venissac N, Pop D, Lassalle S, et al. Sarcomatoid lung cancer (spindle/giant cells): an aggressive disease? J Thorac Cardiovasc Surg. 2007;134:619–623.
   PubMed Web of Science ®Google Scholar
• Xu Z, Ding J, Shi M. [Lung carcinosarcoma–a report of 15 cases]. Zhonghua Zhong Liu Za Zhi. 1996;18:119–122.
   PubMedGoogle Scholar
• Bae H-M, Min HS, Lee S-H, et al. Palliative chemotherapy for pulmonary pleomorphic carcinoma. Lung Cancer. 2007;58:112–115.
   PubMed Web of Science ®Google Scholar
• Hong JY, Choi MK, Uhm JE, et al. The role of palliative chemotherapy for advanced pulmonary pleomorphic carcinoma. Med Oncol. 2009;26:287–291.
   PubMed Web of Science ®Google Scholar
• Vieira T, Girard N, Ung M, et al. Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma. J Thorac Oncol. 2013;8:1574–1577.
   PubMed Web of Science ®Google Scholar
• Liu X, Jia Y, Stoopler MB, et al. Next-generation sequencing of pulmonary sarcomatoid carcinoma reveals high frequency of actionable MET gene mutations. J Clin Oncol. 2016;34(8):794–802.
   PubMed Web of Science ®Google Scholar
• Italiano A, Cortot AB, Ilie M, et al. EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti-EGFR treatment of a rare lung malignancy. Int J Cancer. 2009;125:2479–2482.
   PubMed Web of Science ®Google Scholar
• Lin Y, Yang H, Cai Q, et al. Characteristics and prognostic analysis of 69 patients with pulmonary sarcomatoid carcinoma. Am J Clin Oncol. 2014. doi:10.1097/COC.0000000000000101.
   Web of Science ®Google Scholar
• Chang Y-L, Wu C-T, Shih J-Y, et al. EGFR and p53 status of pulmonary pleomorphic carcinoma: implications for EGFR tyrosine kinase inhibitors therapy of an aggressive lung malignancy. Ann Surg Oncol. 2011;18:2952–2960.
   PubMed Web of Science ®Google Scholar
• Jiang X, Liu Y, Chen C, et al. The value of biomarkers in patients with sarcomatoid carcinoma of the lung: molecular analysis of 33 cases. Clin Lung Cancer. 2012;13:288–296.
   PubMed Web of Science ®Google Scholar
• Kaira K, Horie Y, Ayabe E, et al. Pulmonary pleomorphic carcinoma: a clinicopathological study including EGFR mutation analysis. J Thorac Oncol. 2010;5:460–465.
   PubMed Web of Science ®Google Scholar
• Ushiki A, Koizumi T, Kobayashi N, et al. Genetic heterogeneity of EGFR mutation in pleomorphic carcinoma of the lung: response to gefitinib and clinical outcome. Jpn J Clin Oncol. 2009;39:267–270.
   PubMed Web of Science ®Google Scholar
• Zou F, Xie G, Ma J-A, et al. Epidermal growth factor receptor mutation heterogeneity analysis of pulmonary sarcomatoid carcinoma successfully treated with erlotinib: a case report. Oncol Lett. 2015;9:2239–2243.
   PubMed Web of Science ®Google Scholar
• Fallet V, Saffroy R, Girard N, et al. High-throughput somatic mutation profiling in pulmonary sarcomatoid carcinomas using the LungCarta Panel: exploring therapeutic targets. Ann Oncol. 2015;26:1748–1753.
   PubMed Web of Science ®Google Scholar
• Pelosi G, Gasparini P, Cavazza A, et al. Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene. Lung Cancer. 2012;77:507–514.
   PubMed Web of Science ®Google Scholar
• Sadiq AA, Salgia R. MET as a possible target for non-small-cell lung cancer. J Clin Oncol. 2013;31:1089–1096.
   PubMed Web of Science ®Google Scholar
• Camidge DR, Ou S-HI, Shapiro G, et al Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). J Clin Oncol. 2014;32(suppl; abstr 8001):5s.
   PubMedGoogle Scholar
• Ou S-HI, Kwak EL, Siwak-Tapp C, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol. 2011;6:942–946.
   PubMed Web of Science ®Google Scholar
• Awad MM, Oxnard GR, Jackman DM, et al. MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression. J Clin Oncol. 2016;34:721–730.
   PubMed Web of Science ®Google Scholar
• Tong JH, Yeung SF, Chan AW, et al. MET amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis. Clin Cancer Res. 2016. doi:10.1158/1078-0432.CCR-15-2061.
   Google Scholar
• Frampton GM, Ali SM, Rosenzweig M, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov. 2015;5:850–859.
   PubMed Web of Science ®Google Scholar
• Paik PK, Drilon A, Fan P-D, et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov. 2015;5:842–849.
   PubMed Web of Science ®Google Scholar
• Lee C, Usenko D, Frampton GM, et al. MET 14 deletion in sarcomatoid non–small-cell lung cancer detected by next-generation sequencing and successfully treated with a MET inhibitor. J Thorac Oncol. 2015;10:e113–e114.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–1639.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015. doi:10.1016/S0140-6736(15)01281-7.
   PubMed Web of Science ®Google Scholar
• Kim S, Kim M-Y, Koh J, et al. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: comparison of sarcomatous and carcinomatous areas. Eur J Cancer. 2015;51:2698–2707.
   PubMed Web of Science ®Google Scholar